Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions

December 2018 | 288 pages | ID: G0291966F87EN
BCC Research

Abstracts

Report Scope:

The report on “Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions” presents qualitative and quantitative information on the current market dynamics that are influencing the market. It covers a background to cancer, types of cancer, pathogenesis of cancer, and stages of cancer development, including the mechanisms of metastasis and recurrences. It also includes the disease burden through understanding the epidemiology of various cancers. Treatment patterns, which include the pharmacological approaches (covering cytotoxic/chemotherapy, hormonal therapy, targeted therapy, and combinatorial therapy) and non-pharmacological approaches (including surgeries and radiation) are covered to present the various therapeutic options available for the patients. Also included in the report are analyses of key marketed products; the current clinical trial landscape; patent landscape and recent product approvals; regulatory landscape; and reimbursement landscape across different demographics. An overview of the demographics of key regions, namely, North America, Europe, Asia-Pacific, Latin America and the Middle East, with potential growth is also covered. Strategies of global companies engaged in the cancer therapeutic space and the profiles of top companies are also covered.

The quantitative information covered in the report includes -

• Estimates of the market size of the cancer therapeutics used for treating metastases and recurrence states of cancer. The key cancer types covered include lung cancer, breast cancer, liver cancer, stomach cancer, prostate cancer, colorectal cancer, gastric cancer, cervical cancer, bladder cancer, kidney cancer, ovarian cancer and others. Others includes leukemia, lymphoma, multiple myeloma, brain tumor, thyroid cancer and uteral cancer.
• Further growth potential and forecast information has been covered for the overall cancer therapeutics market and for segments-cancer types, by region and by country.

Market values provided are based on total revenues of cancer therapeutics drug manufacturers.

As a cancer therapeutics (emphasis on recurrent and metastatic cancer) market report, only pharmacological therapy is covered for computation of the market size. Interventions involving surgeries, radiation, ablations and other medical device interventions are excluded from the market size computation and only qualitative information on the same is covered.

Report Includes:

• 36 data tables and 55 additional tables
• An overview of global cancer therapeutics market with special focus on recurrent and metastatic divisions
• Country specific data and analysis for US, Canada, Mexico, Germany, Italy, U.K, France, China, India, Japan, South Korea, Brazil, Argentina and Chile
• Description of stages of cancer development including the mechanisms of metastasis and recurrences
• Insights of current diagnostics such as medical imaging, in vitro diagnostics technologies and treatment patterns
• Snapshot of pharmacological approaches covering cytotoxic/chemotherapy, hormonal therapy, targeted therapy and combinatorial therapy and non-pharmacological treatments such as surgeries, radiation
• Complete understanding of causes, risk factors, prevalence and incidence of cancer
• Information on economic cost burden due to cancer
• Dossier of recent industry events, product innovation, acquisition, partnership and collaborations and competitor strategies
• Comprehensive company profiles of major market players of the industry including AbbVie, Inc., Biogen Inc., GlaxoSmithKline plc (GSK), Eli Lilly and Co., Merck & Co., Inc., and Pfizer Inc.

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Scope of Report
Information Sources
Methodology
Market Estimation and Forecast
Geographic Breakdown
Analyst’s Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 SUMMARY

Key Findings

CHAPTER 3 BIOLOGY OF CANCER

Overview
Lung Cancer
Breast Cancer
Melanoma
Colorectal Cancer
Prostate Cancer
Cervical Cancer
Pathogenesis of Cancer
Genetic Changes
Stages of Cancer
The TNM Staging System
Number Staging Systems
Cancer Metastases
Routes of Metastasis
Drug Resistance
Inherent Resistance
Acquired Resistance

CHAPTER 4 DISEASE AND ECONOMIC BURDEN OF CANCER

Cancer Burden
Tobacco Use and Statistics
Alcohol Abuse and Cancer Statistics
Infectious Diseases and Cancer
Inherited Genes/Diseases and Cancer
Sun, Ultraviolet Radiation and Cancer
Hormones and Cancer
Cancer: A Statistical Analysis of the Disease Incidence and Prevalence
Incidence and Prevalence Rates for Major Cancer Types
Regional Patterns of Cancer
Europe
North America
Asia-Pacific
Latin and Central America
Middle East and Africa

CHAPTER 5 TREATMENT APPROACHES TO CANCER METASTASES AND RECURRENCE

Treatment Approaches to Cancer Metastases and Recurrence
Non-pharmaceutical Approaches
Surgery for Cancer
Radiotherapy for Cancer
Ablation Therapy
Pharmacological Therapies
Cytotoxic Cancer Chemotherapy
Hormone-based Cancer Drugs
Targeted Biologic Therapy
Monoclonal Antibodies
Immune Checkpoint Inhibitors
Cancer Growth Blockers
Gene Therapy
Drugs That Block Cancer Blood Vessel Growth (Antiangiogenics)
Personalized Cancer Therapy (Precision Medicine)
Treatment Options for Selected Cancer Metastases
Breast
Bladder Cancer
Lung
Colorectal Cancer
Standard Treatment Options for Stage IV and Recurrent Colon Cancer
Prostate Cancer
Stomach Cancer
Melanoma
Kidney Cancer
Transitional Cell Cancer (TCC) of the Renal Pelvis and Ureter
Pancreatic Cancer
Thyroid Cancer
Stage I and Stage II Endometrial Cancer
Stage III, Stage IV and Recurrent Endometrial Cancer

CHAPTER 6 CANCER THERAPEUTICS: MARKETED PRODUCTS AND PIPELINE ANALYSIS

Overview
Top Selling Oncology Drugs in 2017
Profiles of Selected Marketed Drugs
Clinical Trials
Lung Cancer
Phase III Clinical Trials
Phase II Clinical Trials
Phase I Clinical Trial
Breast Cancer
Phase III Clinical Trials
Phase II Clinical Trials
Phase I Clinical Trials
Colorectal Cancer
Phase III Clinical Trials
Phase II Clinical Trials
Phase I Clinical Trials
Bladder Cancer
Phase III Clinical Trials
Phase II Clinical Trials
Phase I Clinical Trials
Gastric Cancer
Phase III Clinical Trials
Phase II Clinical Trials
Phase I Clinical Trials
Others (Kidney Cancer, Lymphoma, Leukemia, Ovarian, Pancreatic)
Phase III Clinical Trials
Phase II Clinical Trials
Phase I Clinical Trials

CHAPTER 7 REGULATIONS AND REIMBURSEMENT LANDSCAPE

The United States
Canada
Europe
Mutual Recognition Procedure (MRP)
Decentralized Procedure (DCP)
Centralized Procedure (CP)
Japan
Marketing Authorization System
Pharmaceutical Reimbursement Approval Process in Japan
China
Pharmaceutical Regulatory and Legislative Developments in China
India
Pharmaceutical Regulatory and Legislative Developments in India
South Korea
Regulatory and Legislative Requirements
Pharmaceutical Regulatory and Legislative Developments in South Korea
Pharmaceutical Reimbursement Landscape in South Korea
Brazil
Market Entry and Reimbursement of Pharmaceuticals
Argentina
Regulatory and Legislative Requirements
Mexico
Regulation and Regulation Governing Drugs in Mexico
Health Insurance Structure in Mexico
South Africa
Regulatory Requirementsin South Africa
Health Insurance Structure in South Africa
Reimbursement of Pharmaceuticals in South Africa
Saudi Arabia
Pharmaceutical Regulatory Requirements in Saudi Arabia
Health Insurance Structure in Saudi Arabia

CHAPTER 8 CANCER THERAPEUTICS: ANALYSIS OF GLOBAL AND REGIONAL MARKETS

Overview
Global Cancer Therapeutics Market
Market Drivers
Market Restraints
Market Opportunities
North America
Market Dynamics in North America
United States
Canada
Europe
Market Drivers
Market Restraints
France
Germany
U.K.
Spain
Italy
Asia-Pacific
Market Drivers
Market Restraints
Japan
China
India
Central and Latin America
Market Drivers
Market Restraints
Brazil
Argentina
Middle East and Africa
Market Drivers
Market Restraints

CHAPTER 9 PATENT REVIEW/NEW DEVELOPMENTS

Patent Applications by Clinical Application
Patent Applications Filed on Metastatic Breast Cancer Therapeutics
Patent Applications Filed on Metastatic Prostate Cancer Therapeutics
Patent Applications Filed on Metastatic Lung Cancer Therapeutics
Patents Applications Filed on Therapeutics for Other Cancer Types
Patents and Expiry Dates for Major Products by Leading Suppliers
Pfizer Inc.
Merck & Co.
Johnson & Johnson
F Hoffman-La Roche
Sanofi SA
Novartis AG
AbbVie, Inc.
AstraZeneca plc
Celgene
Eli Lilly
Gilead Sciences
Patents and Expiry Dates for Other Products and Suppliers
Targeting Breakpoint Cluster Region-Abelson (BCR-ABL)
Targeting Epidermal Growth Factor Receptor (EGFR/ERBB1)
Targeting Vascular Endothelial Growth Factor Receptor (VEGFR), PDGFR and Ret Proto-Oncogene (RET)
Impact of Patent Expiries

CHAPTER 10 COMPETITIVE LANDSCAPE

Overview
Leading Companies
Roche
Novartis
Celgene
Bristol-Meyers Squibb
Johnson & Johnson
  Recent Developments

CHAPTER 11 COMPANY PROFILES

ABBVIE, INC.
  Company Overview
Financial Information
Products
Clinical Developments
AMGEN
  Company Overview
Financial Information
Products
ARRAY BIOPHARMA INC.
  Company Overview
Products
AstraZeneca plc
  Company Overview
Financial Information
Key Developments
ASTELLAS PHARMA INC.
  Company Overview
Products
BAYER HEALTHCARE
  Company Overview
Products
BRISTOL-MYERS SQUIBB
  Company Overview
Financial Information
Products
BIOGEN INC.
  Company Overview
CELGENE CORP.
  Company Overview
Financial Information
Products
CELLDEX THERAPEUTICS INC.
  Company Overview
Products
GLAXOSMITHKLINE
  Company Overview
GILEAD SCIENCES, INC.
  Company Overview
Product
ELI LILLY AND CO.
  Company Overview
Financial Information
Products
EISAI CO. LTD.
  Company Overview
Products
F HOFFMAN-LA ROCHE LTD.
  Company Overview
Financial Information
Products
Key Developments
IMMUNOCELLULAR THERAPEUTICS LTD.
  Company Overview
Products
IMMUNOGEN INC.
  Company Overview
INCYTE CORP.
  Company Overview
INFINITY PHARMACEUTICALS, INC.
  Company Overview
JOHNSON & JOHNSON
  Company Overview
Financial Information
Products
MERCK & CO., INC.
Financial Information
Products
NOVARTIS AG
  Company Overview
Financial Information
Products
Clinical Development
Key Developments
NEW LINK GENETICS CORP.
  Company Overview
OTSUKA HOLDINGS CO. LTD.
  Company Overview
PFIZER INC.
  Company Overview
Financial Information
Key Developments
REGENERON PHARMACEUTICALS INC.
  Company Overview
SANOFI SA
  Company Overview
Financial Information
Products
Key Developments
SELLAS LIFE SCIENCES GROUP
  Company Overview
TAKEDA PHARMACEUTICALS
  Company Overview
VERASTEM INC.
  Company Overview

CHAPTER 12 APPENDIX: ACRONYMS

List Of Tables

LIST OF TABLES

Summary Table: Global Cancer Therapeutics Market, by Cancer Type, Through 2023
Table 1: Cancer Incidence in the U.S., by Sex, 2017
Table 2: Number of Deaths from Cancer in the U.S., by Sex, 2017
Table 3: Cancer Treatment Options
Table 4: Cancer Drug Treatment Classes
Table 5: FDA-Approved Intravenous Therapeutic Monoclonal Antibodies Used to Treat Cancer, 1997-2017
Table 6: Approved Tyrosine Kinase Inhibitors (TKIs) Used to Treat Cancer
Table 7: Common Chemotherapeutic Agents for Recurrent and Metastatic Breast Cancer
Table 8: Drugs Approved for the Treatment of Lung Cancer
Table 9: Treatment Options for Stage IV and Recurrent Colon Cancer
Table 10: Hormone Therapy for Prostate Cancer
Table 11: Drugs Approved for Prostate Cancer
Table 12: Drugs Approved for Stomach (Gastric) Cancer
Table 13: Drugs Combinations Approved for Stomach (Gastric) Cancer
Table 14: Drugs Approved for Gastroenteropancreatic Neuroendocrine Tumors
Table 15: Drugs Approved for the Treatment of Melanoma
Table 16: Drugs Approved for Pancreatic Cancer
Table 17: Drugs Approved for Pancreatic Cancer
Table 18: Treatment Option Overview for Thyroid Cancer
Table 19: Drugs Approved for Thyroid Cancer
Table 20: Treatment Option Overview for Endometrial Cancer
Table 21: Profiles of Top Marketed Drugs
Table 22: Lung Cancer Phase III Clinical Trials, 2018*
Table 23: Lung Cancer Phase II Clinical Trials, 2018*
Table 24: Lung Cancer Phase I Clinical Trials, 2018*
Table 25: Breast Cancer Phase III Clinical Trials, 2018*
Table 26: Breast Cancer Phase II Clinical Trials, 2018*
Table 27: Breast Cancer Phase I Clinical Trials, 2018*
Table 28: Colorectal Cancer Phase III Clinical Trials, 2018*
Table 29: Colorectal Cancer Phase II Clinical Trials, 2018*
Table 30: Colorectal Cancer Phase I Clinical Trials, 2018*
Table 31: Bladder Cancer Phase III Clinical Trials, 2018*
Table 32: Bladder Cancer Phase II Clinical Trials, 2018*
Table 33: Bladder Cancer Phase I Clinical Trials, 2018*
Table 34: Gastric Cancer Phase III Clinical Trials, 2018*
Table 35: Gastric Cancer Phase II Clinical Trials, 2018*
Table 36: Gastric Cancer Phase I Clinical Trials, 2018*
Table 37: Others Phase III Clinical Trials, 2018*
Table 38: Others Phase II Clinical Trials, 2018*
Table 39: Others Phase I Clinical Trials, 2018*
Table 40: Global Cancer Therapeutics Market, by Cancer Type, Through 2023
Table 41: North American Cancer Therapeutics Market, by Cancer Type, Through 2023
Table 42: North American Cancer Therapeutics Market, by Country, Through 2023
Table 43: European Cancer Therapeutics Market, by Cancer Type, Through 2023
Table 44: European Cancer Therapeutics Market, by Country, Through 2023
Table 45: Asia-Pacific Cancer Therapeutics Market, by Cancer Type, Through 2023
Table 46: Asia-Pacific Cancer Therapeutics Market, by Country, Through 2023
Table 47: Central and Latin American Cancer Therapeutics Market, by Cancer Type, Through 2023
Table 48: Central and Latin American Cancer Therapeutics Market, by Country, Through 2023
Table 49: Middle East and Africa Cancer Therapeutics Market, by Cancer Type, Through 2023
Table 50: Patent Applications Filed on Metastatic Breast Cancer Therapeutics, 2016 – October 2017
Table 51: Patent Applications Filed on Metastatic Prostate Cancer Therapeutics, November 2015 – January 2018
Table 52: Patent Applications Filed on Metastatic Lung Cancer Therapeutics, August 2015 – January 2018
Table 53: Latest Patent Publications Cited Relating to Other Metastatic Cancers, December 2015 – July 2018
Table 54: Pfizer Inc.: Patent Expiry Dates for Leading Cancer Drugs
Table 55: Merck & Co.: Patent Status of Leading Oncology Products
Table 56: Johnson & Johnson: Patent Status of Leading Oncology Products
Table 57: F Hoffman-La Roche: Patent Status of Leading Oncology Products
Table 58: Sanofi SA: Patent Status of Leading Oncology Products
Table 59: AstraZeneca plc: Patent Status of Leading Oncology Products
Table 60: Celgene: Patent Status of Leading Oncology Products
Table 61: Eli Lilly: Patent Status of Leading Oncology Products
Table 62: Recent Industry Developments, December 2017 Through September 2018
Table 63: AbbVie, Inc.: Company   Financials, by Product, 2015-2017
Table 64: Amgen: Company   Financials, 2015-2017
Table 65: Array Biopharma Inc.: Clinical Stage Drug Portfolio
Table 66: AstraZeneca plc.: Company Net Revenue, 2015-2017
Table 67: AstraZeneca plc: Company   Financials, by Therapeutic Product Group, 2015-2017
Table 68: AstraZeneca plc: Company   Financials, by Oncology Product Group, 2015-2017
Table 69: Bristol-Myers Squibb: Revenue, 2015-2017
Table 70: Bristol-Myers Squibb: Oncology Product Sales, 2015-2017
Table 71: Celgene Corp.: Company   Financials, by Product, 2015-2017
Table 72: GlaxoSmithKline: Oncology Product Pipeline
Table 73: Gilead Sciences, Inc.: Product Pipeline
Table 74: Eli Lilly and Co.: Net Revenue, by Segment, 2015-2017
Table 75: Eli Lilly and Co.: Oncology Product Sales, 2015-2017
Table 76: F Hoffmann-La Roche Ltd.: Net Revenue, by Segment, 2015-2017
Table 77: F Hoffman-La Roche Ltd.: Pharmaceutical Division Oncology Product Sales, 2015-2017
Table 78: Johnson & Johnson: Company   Financials, by Segment, 2015-2017
Table 79: Johnson & Johnson: Pharmaceutical Therapeutic Area Product Sales, 2015-2017
Table 80: Johnson & Johnson: Oncology Product Sales, 2015-2017
Table 81: Merck & Co., Inc.: Therapeutic Area Product Sales, 2015-2017
Table 82: Merck & Co., Inc.: Oncology Product Sales, 2015-2017
Table 83: Novartis AG: Company   Financials, by Business Segment, 2015-2017
Table 84: Novartis AG: Major Development Projects
Table 85: Pfizer Inc.: Company   Financials, 2015-2017
Table 86: Pfizer Inc.: Innovative Health (IH) Division   Financials, 2015-2017
Table 87: Pfizer Inc.: Innovative Health (IH) Division Oncology Product Sales, 2015-2017
Table 88: Sanofi SA: Company   Financials, 2015-2017
Table 89: Sanofi SA: Oncology Product Sales, 2015-2017
Table 90: Commonly Used Acronyms Associated with Metastatic and Recurrent Cancer

List Of Figures

LIST OF FIGURES

Summary Figure: Global Cancer Therapeutics Market Share, by Cancer Type, 2017
Figure 1: Top Selling Oncology Drugs, 2017
Figure 2: Distribution of Clinical Trials for Cancer Metastases and Recurrence, by Cancer Type, 2018*
Figure 3: Global Cancer Therapeutics Market, 2017-2023
Figure 4: Global Cancer Therapeutics Market Share, by Cancer Type, 2017
Figure 5: North American Cancer Therapeutics Market, by Cancer Type, 2017-2023
Figure 6: European Cancer Therapeutics Market, by Cancer Type, 2017-2023
Figure 7: Asia-Pacific Cancer Therapeutics Market, by Cancer Type, 2017-2023
Figure 8: Central and Latin American Cancer Therapeutics Market, by Cancer Type, 2017-2023
Figure 9: Middle East and African Cancer Therapeutics Market, by Cancer Type, 2017-2023
Figure 10: Global Cancer Therapeutics Market Share, by Company, 2017